Business
Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
NEEDHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that an abstract was accepted for an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 to June 3, 2025, in Chicago, IL. The oral presentation will feature data from the Comp
About this update from Candel Therapeutics, Inc.
[{"type":"image","alt":"Candel Therapeutics","displaySize":"","headline":null,"caption":"Candel Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":137,"url":"https://media.zenfs.com/en/globenewswire.com/e791e10481877ea34bb2d8e55bba5dfe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_0g4zgCUCZX.eG19M3SXZg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e791e10481877ea34bb2d8e55bba5dfe","width":300,"height":137}},"lazy":false},{"type":"text","content":"NEEDHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that an abstract was accepted for an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 to June 3, 2025, in Chicago, IL. The oral presentation will feature data from the Company’s phase 3 clinical trial of CAN-2409 in patients with intermediate-to-high risk localized prostate cancer.","length":610,"tagName":"p"},{"type":"text","content":"Details are as follows:","length":23,"tagName":"p"},{"type":"text","content":"CAN-2409 – Localized Prostate Cancer","length":36,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Abstract Title: Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard-of-care external beam radiation therapy (EBRT) for newly diagnosed localized prostate cancer","length":212,"tagName":"p"}]},{"val":[{"type":"text","content":"Presenter: Theodore DeWeese, M.D. *, the Francis Watt Baker, M.D., and Lenox D. Baker Jr., M.D., Dean of the Medical Faculty and CEO, Johns Hopkins Medicine","length":156,"tagName":"p"}]},{"val":[{"type":"text","content":"Session Title: Oral Abstract Session – Genitourinary Cancer – Prostate, Testicular, and Penile","length":94,"tagName":"p"}]},{"val":[{"type":"text","content":"Session Date/Time: Tuesday, June 3, 2025; 9:45 AM - 12:45 PM CT ","length":63,"tagName":"p"}]},{"val":[{"type":"text","content":"Location: Hall A, McCormick Place Convention Center, Chicago, IL","length":64,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":589,"olType":false},{"type":"text","cont...